Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)

Autor: Ay, Cihan, Male, Christoph, Hermans, Cedric, Verhamme, Peter, Lissitchkov, Toshko, Antoniades, Marios, Penka, Miroslav, Blatny, Jan, Komrska, Vladimir, Poulsen, Lone Hvitfeldt, Kampmann, Peter, Lehtinen, Anna-Elina, Susen, Sophie, Dargaud, Yesim, Biron, Christine, D'Oiron, Roseline, Harroche, Annie, Klamroth, Robert, Oldenburg, Johannes, Buehrlen, Martina, Miesbach, Wolfgang, Langer, Florian, Spannag, Patrick, Oliveri, Martin, Platokouki, Helen, Nomikou, Efrosyni, Katsarou, Olga, Garypidou, Vasileia, Economou, Marina, Nemes, Laszlo, Nolan, Beatrice, O'Connell, Niamh, Paolo, Radossi, Castaman, Giancarlo, Peyvandi, Flora, Rocino, Angiola, Zanon, Ezio, Tagliaferri, Annarita, Agnelli, Giancarlo, De Crisotofaro, Raimondo, Schinco, Piercarla, Tosetto, Alberto, Lejniece, Sandra, Gailiute, Neringa, Gatt, Alexander, Mäkelburg, Anja, Laros-van Gorkom, Britta, Brons, Paul, Leebeek, Frank W.G., Schutgens, Roger, Windyga, Jerzy, Catarino, Cristina, Aires, Anabela, Fraga, Cristina, Morais, Sara, Araújo, Fernando, Serban, Margit, Davydkin, Igor, Batorova, Angelika, Anzej Doma, Sasa, Martinez, Laura Segura, Palomo Bravo, Angeles, Ortega, Immaculada Soto, Bonanad, Santiago, Baghaei, Fariba, Astermark, Jan, Holmström, Margareta, Fontana, Pierre, Schmugge, Markus, Zulfikar, Bulent, Kavakli, Kaan, Khan, Mohammed, Benson, Gary, Lester, Will, Andrew, Page, Catherine, Bagot, Pinto, Fernando, Salta, Styliani, Farrelly, Cathy, Matthias, Mary, Laffan, Mike, Thynn Thynn, Yee, Mcdonald, Vickie, Austin, Steve, Bella, Madan, Hay, Charles, Grainger, John, Talks, Kate, Shapiro, Susie, Maclean, Rhona, Payne, Jeanette, Fischer, Kathelijn, Lassila, Riitta, Gouw, Samantha C., Hollingsworth, Rob, Lambert, Thierry, Kaczmarek, Radek, Carbonero, Diana, Makris, Mike

Publikováno v: In Research and Practice in Thrombosis and Haemostasis May 2024 8(4)

Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis

Autor: Peyvandi, F. ^*, Cannavò, A., Garagiola, I., Palla, R., Mannucci, P.M., Rosendaal, F.R., El‐Beshlawy, A., Elalfy, M., Ramanan, V., Eshghi, P., Hanagavadi, S., Varadarajan, R., Karimi, M., Manglani, M.V., Ross, C., Young, G., Seth, T., Apte, S., Nayak, D.M., Santagostino, E., Elisa Mancuso, M., Sandoval Gonzalez, A.C., Mahlangu, J.N., Bonanad Boix, S., Cerqueira, M., Ewing, N.P., Male, C., Owaidah, T., Soto Arellano, V., Kobrinsky, N.L., Majumdar, S., Perez Garrido, R., Sachdeva, A., Simpson, M., Thomas, M., Zanon, E., Antmen, B., Kavakl, K., Manco‐Johnson, M.J., Martinez, M., Marzouka, E., Mazzucconi, M.G., Neme, D., Palomo Bravo, A., Paredes Aguilera, R., Prezotti, A., Schmitt, K., Wicklund, B.M., Zulfikar, B.

Publikováno v: In Journal of Thrombosis and Haemostasis January 2018 16(1):39-43

PB1326 Real-World Data on Correlation between Emicizumab Plasma Levels, Ex-Vivo Procoagulant Profile and Spontaneous Joint Annualized Bleeding Rate of Patients on Emicizumab Prophylaxis

Autor: López Jaime, F., Marco, A., Montaño, A., Palomo Bravo, Á., Muñoz López, F., Marco, P., Fernández-Bello, I.

Publikováno v: In Research and Practice in Thrombosis and Haemostasis October 2023 7 Supplement 2

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.